|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations impairing liver synthesis or secretion of apolipoprotein B are crucial to increase the risk of liver steatosis.
|
28733173 |
2018 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the low-frequency E167K variant of TM6SF2 and rare mutations in APOB, which impair very low-density lipoproteins secretion, predispose to progressive fatty liver.
|
26409295 |
2016 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PCSK9 mRNA levels were also correlated with steatosis severity (p = 0.04) and hepatic APOB (p < 0.001), SREBP-1c (p = 0.047) and FAS expression (p = 0.001).
|
27222915 |
2016 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Partial MTP inhibition using small molecule inhibitors, such as lomitapide, can effectively lower plasma low-density lipoprotein-cholesterol and apolipoprotein B levels, but is associated with gastrointestinal side effects and hepatic steatosis, whose long-term sequelae remain unclear; lomitapide has accordingly only been approved as a treatment for homozygous familial hypercholesterolemia.
|
25552696 |
2015 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We used exome sequencing to discover a novel nonsense mutation in exon 26 of APOB (p.K2240X) responsible for low cholesterol and fatty liver in a large kindred.
|
23723369 |
2013 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings identify miR-30c as a novel therapeutic target that coordinately reduces lipid biosynthesis and lipoprotein secretion to suppress circulating apoB lipoproteins, while sparing the liver from steatosis.
|
24201112 |
2013 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) infection is associated to dysregulation of apoB-100 secretion and steatosis; however, the molecular mechanism by which HCV affects the apoB-100 secretion is not understood.
|
22443280 |
2012 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the frequency of two polymorphisms in Brazilian patients with biopsy-proven simple steatosis or non-alcoholic steatohepatitis (NASH): -493 G/T in the MTP gene, which codes the protein responsible for transferring triglycerides to nascent apolipoprotein B, and -129 C/T in the GCLC gene, which codes the catalytic subunit of glutamate-cystein ligase in the formation of glutathione.
|
19817962 |
2010 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Liver biopsy of the apoB-13.7 heterozygote, which had obesity and insulin resistance, showed severe fatty liver.
|
18848826 |
2009 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, very low-density lipoprotein (VLDL) subclass analysis showed that the VLDL2 fraction of the fatty liver subgroup contained significantly less cholesterol and triglycerides (P = .02 for both parameters), which was likely explained by a decreased VLDL2 particle number because VLDL2 apolipoprotein B levels tended to be lower (P = .08).
|
17884438 |
2007 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
CTD_human |
This steatosis was associated with aberrant microsomal apolipoprotein (apo) B-100 and microsomal triglyceride transfer protein (MTP) content, hypotriglyceridemia, hypocholesterolemia and abnormalities in both circulating lipoprotein composition and size.
|
17303181 |
2007 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Familial hypobetalipoproteinaemia (FHBL) is a codominant disorder characterised by fatty liver and reduced plasma levels of low-density lipoprotein (LDL) and its protein constituent apolipoprotein B (apoB).
|
17158591 |
2007 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that hepatic steatosis in apoB/BATless mice is associated with elevated rates of hepatic lipogenesis that are linked directly to increased hepatic expression of PPARgamma2.
|
16971390 |
2006 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fatty liver is common in apoB-defective FHBL.
|
15877300 |
2005 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fatty liver is frequent in the apolipoprotein B (apoB)-defective genetic form of familial hypobetalipoproteinemia (FHBL), but interindividual variability in liver fat is large.
|
14967820 |
2004 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
CTD_human |
The cells with steatosis showed increased levels of intracellular triglycerides and apolipoprotein B, which were reduced in the presence of bezafibrate at 100 mug/ml.
|
12048068 |
2002 |
|
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Familial hypobetalipoproteinemia (FHBL) is a genetically heterogeneous condition characterized by very low apolipoprotein B (apoB) concentrations in plasma and/or low levels of LDL-cholesterol (LDL-C) with a propensity to developing fatty liver.
|
11893777 |
2002 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study suggests that: i) fatty liver invariably develops in FHBL carriers of short and medium-size truncated apoBs (< apoB-48), but its occurrence needs additional environmental factors in carriers of longer apoB forms; ii) intestinal lipid malabsorption develops only in carriers of short truncated apoBs, which are not secreted into the plasma; and iii) cerebrovascular disease due to premature atherosclerosis may occur even in FHBL subjects.
|
11590210 |
2001 |
|
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We suggest that (1) steatosis is associated with increased ApoA-I mRNA; (2) fibrosis is associated with decreased serum ApoA-I, probably caused by a posttranscriptional mechanism; (3) severe alcohol-induced cirrhosis is associated with a nonspecific decrease in ApoA-I and ApoB mRNA; and (4) in contrast to ApoA-I mRNA, the ApoB mRNA level makes a slight contribution to the ApoB serum concentration.
|
8550047 |
1996 |
|
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|